problendoПроблемы ЭндокринологииProblems of Endocrinology0375-96602308-1430Endocrinology Research Centre10.14341/probl200753533-40problendo-10971Research ArticleКлиническая эндокринологияClinical endocrinologyЛечение гипергликемии при сахарном диабете 2-го типа: алгоритм-консенсус для начальной и последующей терапии (Консенсус Американской диабетологической ассоциации и Европейской ассоциации изучения диабетаManagement of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. (A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes)NathanD. М.NathanD. M.probl@endojournals.ruBuseI. В.BuseJ. В.probl@endojournals.ruDavidsonМ. В.DavidsonM. В.

Clinical Trials Unit

probl@endojournals.ruHeineA. J.HeineR. J.

Diabetes Center

probl@endojournals.ruHolmanR. R.HolmanR. R.

Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism

probl@endojournals.ruSherwinR.SherwinR.

Departament of Internal Medicine and Endocrinology

probl@endojournals.ruZinmanВ.ZinmanB.

Departments of Endocrinology and Metabolism, Mount Sinai Hospital

probl@endojournals.ru<p>Diabetes Center, Massachusetts General Hospital and Harvard Medical School</p>Соединённые Штаты Америки<p>Diabetes Center, Massachusetts General Hospital and Harvard Medical School</p>United States<p>University of North Carolina School of Medicine</p>Соединённые Штаты Америки<p>University of North Carolina School of Medicine</p>United States<p>Charles R. Drew University</p>Россия<p>Charles R. Drew University</p>Russian Federation<p>VU University Medical Center</p>Нидерланды<p>VU University Medical Center</p>Netherlands<p>Oxford University</p>Великобритания<p>Oxford University</p>United Kingdom<p>Yale University School of Medicine</p>Соединённые Штаты Америки<p>Yale University School of Medicine</p>United States<p>University of Toronto</p>Соединённые Штаты Америки<p>University of Toronto</p>United States200715102007535ТОМ 53, №5 (2007)3340Copyright &#x00A9; Nathan D.М., Buse I.В., Davidson М.В., Heine A.J., Holman R.R., Sherwin R., Zinman В., 20072007Nathan D.М., Buse I.В., Davidson М.В., Heine A.J., Holman R.R., Sherwin R., Zinman В.Nathan D.M., Buse J.В., Davidson M.В., Heine R.J., Holman R.R., Sherwin R., Zinman B.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.probl-endojournals.ru/jour/article/view/10971

Оригинальная статья опубликована в Diabetes Саге. — 2006. — Vol. 29, №8. Переводчик Ю. Сыч. Сокращенный вариант статьи подготовлен А. Горбовской.

Настоящие рекомендации и алгоритм основаны на данных клинических исследований различных возможностей терапии СД 2-го типа и на собственном опыте участников консенсуса с учетом основной цели лечения — достижения и поддержания уровня глюкозы, максимально близкого к уровню гликемии у здоровых людей. Недостаточность доказательств высокого уровня гликемии, полученных в сравнительных клинических исследованиях с непосредственным сравнением различных вариантов лечения СД, остается основной помехой в выделении одного основного класса препаратов или комбинации лекарств, обладающих преимуществами по сравнению с остальными.

This Russian translation and reprint of the original article published with authors permissions. Original article published in the Diabetes Care. 2006;29(8). Translation to Russian prepared by Yu. Sych. An abridged version of the article was prepared by A. Gorbovskaya.

These recommendations and the algorithm are based on data from clinical studies of various treatment options for type 2 diabetes and on the personal experience of consensus participants, taking into account the main goal of treatment - to achieve and maintain glucose levels as close as possible to glycemia in healthy people. The lack of evidence of high levels of glycemia obtained in comparative clinical trials with a direct comparison of different treatment options for diabetes remains the main obstacle to isolating one main class of drugs or combination of drugs that have advantages over others.

сахарный диабет 2 типаклинические рекомендацииамериканская диабетическая ассоциацияконсенсусtype 2 diabetesclinical recommendationsAmerican Diabetes AssociationconsensusReferencesAmerican Diabetes Association. Standards of medical care of diabetes. Diabetes Care 28 (Suppl. 1): S15-S35, 2005.American Diabetes Association. Standards of medical care of diabetes. Diabetes Care 28 (Suppl. 1): S15-S35, 2005.European Diabetes Policy Group: A desk-top guide to type 2 diabetes mellitus. Diabet Med. 16: 716-730, 1999.European Diabetes Policy Group: A desk-top guide to type 2 diabetes mellitus. Diabet Med. 16: 716-730, 1999.The Royal College of General Practitioners Effective Clinical Practice Unit: Clinical guidelines for type 2 diabetes mellitus: management of blood glucose, 2002. Available from http://www.nice.org.uk/pdf/NICE_full_blood_glucose.pdfThe Royal College of General Practitioners Effective Clinical Practice Unit: Clinical guidelines for type 2 diabetes mellitus: management of blood glucose, 2002. Available from http://www.nice.org.uk/pdf/NICE_full_blood_glucose.pdfDiabetes Control and Complications Trial Research Group: The effect of intensive diabetes treatment on the development and progression of long-term complications in insulin-dependent diabetes mellitus: the Diabetes Control and Complications Trial. N. Engl. J. Med. 329: 978-986, 1993.Diabetes Control and Complications Trial Research Group: The effect of intensive diabetes treatment on the development and progression of long-term complications in insulin-dependent diabetes mellitus: the Diabetes Control and Complications Trial. N. Engl. J. Med. 329: 978-986, 1993.Reichard P., Nilsson B.-Y., Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N. Engl. J. Med. 329: 304-309, 1993.Reichard P., Nilsson B.-Y., Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N. Engl. J. Med. 329: 304-309, 1993.UK Prospective Diabetes Study (UKPDS) Group: Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complication in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837- 853, 1998.UK Prospective Diabetes Study (UKPDS) Group: Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complication in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837- 853, 1998.UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood glucose control with metformin on complication in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352: 854-865, 1998.UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood glucose control with metformin on complication in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352: 854-865, 1998.Ohkubo Y., Kishikawa H., Araki E. et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with NIDDM: a randomized prospective 6-year study. Diabetes Res. Clin. Pract. 28: 103-117, 1995.Ohkubo Y., Kishikawa H., Araki E. et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with NIDDM: a randomized prospective 6-year study. Diabetes Res. Clin. Pract. 28: 103-117, 1995.Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group: Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes. N. Engl. J. Med. 348: 2294-2303, 2003.Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group: Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes. N. Engl. J. Med. 348: 2294-2303, 2003.Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N. Engl. J. Med. 353: 2643-2653, 2005.Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N. Engl. J. Med. 353: 2643-2653, 2005.Advance Collaborative Group: ADVANCE: Action in Diabetes and Vascular Disease: patient recruitment and characteristics of the study population at baseline. Diabet. Med. 22: 882- 888, 2005.Advance Collaborative Group: ADVANCE: Action in Diabetes and Vascular Disease: patient recruitment and characteristics of the study population at baseline. Diabet. Med. 22: 882- 888, 2005.American Diabetes Association: Standards of medical care in diabetes-2006. Diabetes Care 29 (Suppl. I): S4-S42, 2006.American Diabetes Association: Standards of medical care in diabetes-2006. Diabetes Care 29 (Suppl. I): S4-S42, 2006.National Institutes of Health: Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report. Bethesda, National Institutes of Health, 1999.National Institutes of Health: Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report. Bethesda, National Institutes of Health, 1999.Groop L. Sulfonylureas in NIDDM. Diabetes Care 15: 737- 747, 1992.Groop L. Sulfonylureas in NIDDM. Diabetes Care 15: 737- 747, 1992.Bailey C. J., Turner R. С Metformin. N. Engl. J. Med. 334: 574-583, 1996.Bailey C. J., Turner R. С Metformin. N. Engl. J. Med. 334: 574-583, 1996.Malaisse W. J. Pharmacology of the meglitinide analogs: new treatment options for type 2 diabetes mellitus. Treat. Endocrinol. 2: 401-414, 2003.Malaisse W. J. Pharmacology of the meglitinide analogs: new treatment options for type 2 diabetes mellitus. Treat. Endocrinol. 2: 401-414, 2003.Van de Laar F. A., Lucassen P. L, Akkermans R. P. et al. Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst. Rev. CD003639, 2005.Van de Laar F. A., Lucassen P. L, Akkermans R. P. et al. Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst. Rev. CD003639, 2005.Genuth S. Insulin use in NIDDM. Diabetes Care 13: 1240- 1264, 1990.Genuth S. Insulin use in NIDDM. Diabetes Care 13: 1240- 1264, 1990.Ykl-Jarvinen H. Drug therapy: thiazolidinediones. N. Engl. J. Med. 351:1106, 2004.Ykl-Jarvinen H. Drug therapy: thiazolidinediones. N. Engl. J. Med. 351:1106, 2004.Drucker D. J. Biologic actions and therapeutic potential of the proglucagon-derived peptides. Nature Endocrinol. Metab. 1: 22-31, 2005.Drucker D. J. Biologic actions and therapeutic potential of the proglucagon-derived peptides. Nature Endocrinol. Metab. 1: 22-31, 2005.Schmitr O., Brock В., Rungby J. Amylin agonists: a novel approach in the treatment of diabetes. Diabetes 53 (Suppl. 3): S233-S238, 2004.Schmitr O., Brock В., Rungby J. Amylin agonists: a novel approach in the treatment of diabetes. Diabetes 53 (Suppl. 3): S233-S238, 2004.Colagiuri S., Cull С A., Holman R. R., UKPDS Group. Are lower fasting plasma glucose levels at diagnosis of type 2 daia-betes associated with improved outcomes? Diabetes Care 25: 1410-1417, 2002.Colagiuri S., Cull С A., Holman R. R., UKPDS Group. Are lower fasting plasma glucose levels at diagnosis of type 2 daia-betes associated with improved outcomes? Diabetes Care 25: 1410-1417, 2002.Harris M. I. Epidemiologic correlates of NIDDM in Hispanics, whites and blacks in the U. S. population. Diabetes Care 14 (Suppl. 3): 639-648, 1991.Harris M. I. Epidemiologic correlates of NIDDM in Hispanics, whites and blacks in the U. S. population. Diabetes Care 14 (Suppl. 3): 639-648, 1991.Rewers M., Hamman F. R. Risk factors for non-insulin dependent diabetes. In: Diabetes in America, 2-nd ed. Harris M., Ed. Bethesda, National Institutes of Health, 1995, P. 179- 220.Rewers M., Hamman F. R. Risk factors for non-insulin dependent diabetes. In: Diabetes in America, 2-nd ed. Harris M., Ed. Bethesda, National Institutes of Health, 1995, P. 179- 220.Pories W. J., Swanson M. S., MacDonald K. G. et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann. Surg. 222: 339-350, 1995.Pories W. J., Swanson M. S., MacDonald K. G. et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann. Surg. 222: 339-350, 1995.Sjostrom L., Llndroos A. K., Peltonen M. et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N. Engl. J. Med. 351: 2683-2693,2004.Sjostrom L., Llndroos A. K., Peltonen M. et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N. Engl. J. Med. 351: 2683-2693,2004.Pontiroli A. E., Folli F., Paganelll M. et al. Laparoscopic gastric banding prevents type 2 diabetes and arterial hypertension and induces their remission in morbid obesity. Diabetes Care 28: 2703-2709, 2005.Pontiroli A. E., Folli F., Paganelll M. et al. Laparoscopic gastric banding prevents type 2 diabetes and arterial hypertension and induces their remission in morbid obesity. Diabetes Care 28: 2703-2709, 2005.Diabetes Prevention Program Research Group: Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care 28: 888-894, 2005.Diabetes Prevention Program Research Group: Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care 28: 888-894, 2005.DeFronzo R., Goodman A. Multicenter Metformin Study Group: Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N. Engl. J. Med. 333: 541, 1995.DeFronzo R., Goodman A. Multicenter Metformin Study Group: Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N. Engl. J. Med. 333: 541, 1995.Salpeter S., Greyber E., Pasternak G., Salpeter E Risk of fatal and nonfatal lactic acidosis with metfromin use in type 2 diabetes mellitus. Cochrane Database Syst. Rev. CD002967, 2006.Salpeter S., Greyber E., Pasternak G., Salpeter E Risk of fatal and nonfatal lactic acidosis with metfromin use in type 2 diabetes mellitus. Cochrane Database Syst. Rev. CD002967, 2006.Diabetes Prevention Program Research Group. Reduction in incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346: 393-403, 2002.Diabetes Prevention Program Research Group. Reduction in incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346: 393-403, 2002.Rosenstock J., Hassman D. R., Madder R. D. et al. Repaghnide versus nateglinide monotherapy: a randomized, multicenter study. Diabetes Care 27: 1265-1270, 2004.Rosenstock J., Hassman D. R., Madder R. D. et al. Repaghnide versus nateglinide monotherapy: a randomized, multicenter study. Diabetes Care 27: 1265-1270, 2004.Gerich J., Raskin P., Jean-Louis L. et al. PRESERVE-p: two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care 28: 2093-2100, 2005.Gerich J., Raskin P., Jean-Louis L. et al. PRESERVE-p: two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care 28: 2093-2100, 2005.Chlasson J. L., Josse R. G., Gomis R. et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM Trial. J. A. M. A. 290: 486-494, 2003.Chlasson J. L., Josse R. G., Gomis R. et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM Trial. J. A. M. A. 290: 486-494, 2003.Nathan D. M., Roussell A., Godine J. E. Glyburide or insulin for metabolic control in non-insulin-dependent diabetes mellitus: a randomized double-blind study. Ann. Intern. Med. 108: 334-340, 1988.Nathan D. M., Roussell A., Godine J. E. Glyburide or insulin for metabolic control in non-insulin-dependent diabetes mellitus: a randomized double-blind study. Ann. Intern. Med. 108: 334-340, 1988.Abraira C, Johnson N., Cohvell J., VA CSDM Group. VA Cooperative study on glycemic control and complications in type II diabetes. Diabetes Care 18:1113-1123, 1995.Abraira C, Johnson N., Cohvell J., VA CSDM Group. VA Cooperative study on glycemic control and complications in type II diabetes. Diabetes Care 18:1113-1123, 1995.Zammitt N. N, Frier В. М. Hypoglycemia in type 2 diabetes. Diabetes Care 28: 2948-2961, 2005.Zammitt N. N, Frier В. М. Hypoglycemia in type 2 diabetes. Diabetes Care 28: 2948-2961, 2005.Miller С. D., Phillips L S., Ziemer D. С. et al. Hypoglycemia in patients with type 2 diabetes mellitus. Arch. Intern. Med. 161:1653-659, 2005.Miller С. D., Phillips L S., Ziemer D. С. et al. Hypoglycemia in patients with type 2 diabetes mellitus. Arch. Intern. Med. 161:1653-659, 2005.Kendall D. M., Riddle M. C, Rosenstock J. et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28: 1083-1091, 2005.Kendall D. M., Riddle M. C, Rosenstock J. et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28: 1083-1091, 2005.DeFronzo R., Ratner R. E., Han J. et al. Effects of exenatide on glycemic control and weight oover 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28: 1092- 1100. 2005.DeFronzo R., Ratner R. E., Han J. et al. Effects of exenatide on glycemic control and weight oover 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28: 1092- 1100. 2005.Buse J. В., Henry R. R., Han J. et al. Effects of exenatide on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27: 2628-2635, 2004.Buse J. В., Henry R. R., Han J. et al. Effects of exenatide on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27: 2628-2635, 2004.Heine R. J., Van Goal L. F., Johns D. et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes. Ann. Intern. Med. 143: 559-569, 2005.Heine R. J., Van Goal L. F., Johns D. et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes. Ann. Intern. Med. 143: 559-569, 2005.Hollander P. A., Levy P., Fineman M. S. et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes. Diabetes Care 26: 784-790, 2003.Hollander P. A., Levy P., Fineman M. S. et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes. Diabetes Care 26: 784-790, 2003.Schwartz S., Sievers R., Strange P. et al. Insulin 70/30 mix plus metformin versus triple oral therapy in the treatment of type 2 diabetes after failure of two oral drugs. Diabetes Care 26: 2238-2243, 2003.Schwartz S., Sievers R., Strange P. et al. Insulin 70/30 mix plus metformin versus triple oral therapy in the treatment of type 2 diabetes after failure of two oral drugs. Diabetes Care 26: 2238-2243, 2003.Ykl-Jarvinen H., Ryysy L., Nikkila K. et al. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. Ann. Intern. Med. 130: 389-396, 1999.Ykl-Jarvinen H., Ryysy L., Nikkila K. et al. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. Ann. Intern. Med. 130: 389-396, 1999.Strowig S., Aviles-Santa M. L., Raskin P. Improved glycemic control without weight gain using triple therapy in type 2 diabetes. Diabetes Care 27: 1577-1583, 2004.Strowig S., Aviles-Santa M. L., Raskin P. Improved glycemic control without weight gain using triple therapy in type 2 diabetes. Diabetes Care 27: 1577-1583, 2004.Fonseca V., Rosenstock J., Patwardhan R., Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus. J. A. M. A. 283: 1695-1702, 2000.Fonseca V., Rosenstock J., Patwardhan R., Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus. J. A. M. A. 283: 1695-1702, 2000.Bailey C. J., Bagdonas A., Rubes J. et al. Rosightazone/met-formin fixed dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: a 24 week, multicent-er, randomized, double blind, parallel group study. Clin. Ther. 27: 1548-1561, 2005.Bailey C. J., Bagdonas A., Rubes J. et al. Rosightazone/met-formin fixed dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: a 24 week, multicent-er, randomized, double blind, parallel group study. Clin. Ther. 27: 1548-1561, 2005.

The authors declare that there are no conflicts of interest present.